Biosysion was founded by a group of Cambridge alumni.
Our proprietary technologies combined both proprietary
microfluidics and real-time polymerase chain reaction (real-time
PCR) together to produce a true point of care DNA detection
platform. Our innovative platform will offer unique solutions to
accelerate the availability of reliable and accurate advanced
molecular diagnostics at the point of care.
At Biosysion, we are at the forefront of molecular diagnostics, dedicated to revolutionizing the early detection of cancer and other critical diseases. Our mission is clear: to develop innovative diagnostic solutions that empower healthcare professionals and patients alike to detect diseases in their earliest and most treatable stages.